U.S. drug maker Merck is building a $1 billion facility in Wilmington, Delaware, aimed at increasing domestic production of ...

Merck CEO Robert Davis joins 'Mornings with Maria' to discuss the new $1 billion biologics manufacturing facility slated to be built in Wilmington, Delaware, and bringing manufacturing back to the U.S ...

Merck estimates the project will create more than 500 full-time roles and about 4,000 construction jobs. CEO of Main Line ...

New Jersey-based pharmaceutical giant Merck is investing $1 billion in what company executives described as a continued ...

Merck starts construction on a $1B biologics facility in Wilmington, Del., expected to create 500+ jobs and support Keytruda production.

Merck is expanding domestic manufacturing with a $895 million investment in its Kansas factory, one of several major projects ...

The 470,000-square-foot facility will support the launch and commercial production of next-generation biologics and therapies ...

The Wilmington lab is expected to be functional by 2028. "The Merck Wilmington Biotech site represents our continued commitment to growing our investments in U.S. manufacturing and has the ...

Merck has initiated construction of a $1 billion, 470,000-square-foot biologics center of excellence in Wilmington, Delaware.

Jared Wood is one of more than 3,000 students receiving undergraduate and graduate degrees. He is the first student in the ...

Located at Chestnut Run Innovation & Science Park, the Merck Wilmington Biotech project will comprise laboratory, ...

Merck estimates the project will create more than 500 full-time roles and about 4,000 construction jobs. CEO of Main Line public company to step down MRA lands $63M in loans to advance former ...